TABLE 1.
Characteristics of patients
| FL n = 34 | WM n = 37 | HC n = 13 | |
|---|---|---|---|
| Age in years, median (IQR) | 65 (54–71) | 71 (63–74) | 72 (57–74) |
| Gender, male n (%) | 16 (47) | 19 (51.3) | 5 (38.5) |
| Treatment status | |||
| Treatment naïve, n (%) | 11 (32.3) | 9 (24.3) | |
| Anti‐CD20 monoclonal + other, n (%) | 23 (65.7) | 14 (37.8) | |
| Rituximab chemotherapy ± maint., n (%) | 19 (55.9) | 11 (29.7) | |
| Obinutuzumab chemotherapy ± maint., n (%) | 4 (11.8) | – | |
| Completed treatment with anti‐CD20 <6 months, n (%) | 10 (29.4) | 0 (0) | |
| Median time from therapy, months (IQR) | 15.5 (7.5–30.5) | 22 (12–39) | |
| Bruton tyrosine kinase inhibitors, n (%) | 2 (6) | 12 (32.4) | |
| Median time on BTKi, months (IQR) | 56.5 (20–93) | 64.5 (46–75) | |
| Other—Venetoclax, n (%) | – | 2 (5) | |
| Median previous lines, n (IQR) | 1 (1–2) | 2 (1–4) | |
| Median baseline IgG, g/L (IQR) | – | 8.11 (3.93–18.5) | |
| IVIg supplementation, n (%) | 1 (3) | 7 (18.9) | |
| Lymphocyte count, n ×109/L (IQR) | 1.4 (0.78–1.73) | 1.4 (0.93–1.7) |
Abbreviations: BTKi, Bruton's tyrosine kinase inhibitor; FL, follicular lymphoma; HC healthy control; IgG, immunoglobulin G; IQR, interquartile range; WM, Waldenström's macroglobulinemia.